Document is current
Any future updates will be listed below
-
Authors
Chang, Xuanhan
Bryant, Linda https://orcid.org/0009-0008-1249-5975
Mena Ortega, Sergio
Howes, Oliver https://orcid.org/0000-0002-2928-1972
Sedlacik, Jan
Veronese, Mattia
Schroeter, Matthias L. https://orcid.org/0000-0001-7977-1083
Lalousis, Paris Alexandros https://orcid.org/0000-0001-9642-3080
Koutsouleris, Nikolaos
Vano, Luke https://orcid.org/0000-0003-1624-490X
Coutts, Fiona https://orcid.org/0009-0009-8951-1467
-
Funding
Funding for this research was provided by:
RCUK | Engineering and Physical Sciences Research Council (EP/Y035216/1)
- License Information
-
More Information
Article History
Received: 26 January 2026
Revised: 24 March 2026
Accepted: 16 April 2026
First Online: 25 April 2026
Competing interests
: OH has received investigator-initiated research funding from and/or participated in advisory/speaker meetings organized by Angelini, Autifony, Biogen, Boehringer-Ingelheim, Bristol-Myer Squibb, Eli Lilly, Heptares, Global Medical Education, Invicro, Karuna, Janssen, Lundbeck, Neurocrine, Otsuka, Sunovion, Teva, Recordati, Roche, and Viatris/Mylan. OH and Veronese have a patent for the use of dopaminergic imaging (REF: WO/2021/111116). The other authors declare no competing interests.
